Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis.

Abstract:

BACKGROUND:Improved treatment approaches for ulcerative colitis (UC), including novel medications, might reduce the need for colectomy. We performed a retrospective cohort study of adult patients (age 18-64) with UC in the United States to examine time trends for colectomy and biologic use from 2007 to 2016. METHODS:We estimated quarterly rates for colectomy and biologic use using the IQVIA Legacy PharMetrics Adjudicated Claims Database. We used interrupted time series methods with segmented regression to assess time trends with 95% confidence intervals (CIs) for biologic use and colectomy before and after the emergence of newly available biologic therapies in 2014. RESULTS:Among 93,930 patients with UC, 2275 (2.4%) underwent colectomy from 2007 to 2016. Biologic use rates increased significantly from 2007 to 2016, from 131 per 1000 person-years in 2007 (95% CI, 121 to 140) to 589 per 1000 person-years in 2016 (95% CI, 575 to 604; P < 0.001). Colectomy rates decreased significantly between 2007 and 2016, from 7.8 per 1000 person-years (95% CI, 7.4 to 8.2) to 4.2 per 1000 person-years in 2016 (95% CI, 3.2 to 5.1; P < 0.001). An interruption in 2014 was associated with a positive trend deflection for biologic use (+72 treatments per 1000 person-years per year (95% CI, 61 to 83) and a negative trend deflection for colectomy (-0.76 per 1000 person-years per year; 95% CI, -1.47 to -0.05). CONCLUSIONS:Among commercially insured patients in the United States from 2007 to 2016, biologic use rates increased, colectomy rates decreased, and both trends were impacted by the interruption in 2014. These findings suggest that new biologic therapies may have contributed to decreased colectomy rates.

journal_name

Inflamm Bowel Dis

authors

Barnes EL,Jiang Y,Kappelman MD,Long MD,Sandler RS,Kinlaw AC,Herfarth HH

doi

10.1093/ibd/izz247

subject

Has Abstract

pub_date

2020-07-17 00:00:00

pages

1225-1231

issue

8

eissn

1078-0998

issn

1536-4844

pii

5601649

journal_volume

26

pub_type

杂志文章
  • Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective.

    abstract::Inflammatory bowel disease (IBD) is now recognized as a common chronic disease affecting children and adolescents. This article will review recent advances made in the fields of genetics, epidemiology, gut ecology, and immunology regarding the etiopathogenesis of IBD, with particular emphasis on the contributions made...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/00054725-200203000-00008

    authors: Oliva-Hemker M,Fiocchi C

    更新日期:2002-03-01 00:00:00

  • The implications of acute pouchitis on the long-term functional results after restorative proctocolectomy.

    abstract::A prospective study was conducted to determine the implications of acute pouchitis on the long-term functional results of restorative proctocolectomy with J-pouch ileoanal anastomosis (IPAA). Between July 1988 and June 1996, 137 consecutive patients underwent IPAA for treatment of ulcerative colitis. 127 patients (93%...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.3780040405

    authors: Hurst RD,Chung TP,Rubin M,Michelassi F

    更新日期:1998-11-01 00:00:00

  • Sarcopenia and Inflammatory Bowel Disease: A Systematic Review.

    abstract:Background:Sarcopenia is associated with increased morbidity and mortality in oncologic and transplant surgery. It has a high incidence in chronic inflammatory states including inflammatory bowel disease (IBD). The validity of existing data in IBD and of sarcopenia's correlation with surgical outcomes is limited. Meth...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy212

    authors: Ryan E,McNicholas D,Creavin B,Kelly ME,Walsh T,Beddy D

    更新日期:2019-01-01 00:00:00

  • Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics.

    abstract:BACKGROUND:The cumulative incidence of colectomy and the impact of 5-aminosalicylates (5-ASA), azathioprine, and antitumor necrosis factor (TNF) treatment on the long-term need for surgery are unknown in ulcerative colitis (UC) in the era of biologics. METHODS:This was an observational study of a referral center cohor...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21932

    authors: Williet N,Pillot C,Oussalah A,Billioud V,Chevaux JB,Bresler L,Bigard MA,Gueant JL,Peyrin-Biroulet L

    更新日期:2012-09-01 00:00:00

  • Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy.

    abstract:BACKGROUND:Osteoporosis is a well-known complication of Crohn's disease (CD). Osteoprotegerin (OPG) concentration is elevated in patients with CD compared to healthy controls. Long-term infliximab (IFX) maintenance therapy improves the patients' bone mineral density. The effect of IFX on bone metabolism has not yet bee...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1002/ibd.20234

    authors: Miheller P,Muzes G,Rácz K,Blázovits A,Lakatos P,Herszényi L,Tulassay Z

    更新日期:2007-11-01 00:00:00

  • Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis.

    abstract:INTRODUCTION:Concurrent cytomegalovirus (CMV) in inflammatory bowel disease-related colitis is an important yet complex clinical scenario associated with high rates of colectomy and other morbidity. This review aimed to examine the literature to produce a comprehensive diagnostic and treatment algorithm for the managem...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000000958

    authors: Beswick L,Ye B,van Langenberg DR

    更新日期:2016-12-01 00:00:00

  • Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.

    abstract:BACKGROUND:High doses of mesalazine usually result in an inconvenient dosage schedule and reduced compliance. The goal of this trial was to compare the effects of mesalazine 4 g daily given as prolonged-release granules in packets of 1 g with that of prolonged-release tablets of 0.5 g. METHODS:Two hundred twenty-seven...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00054725-200108000-00009

    authors: Farup PG,Hinterleitner TA,Lukás M,Hébuterne X,Rachmilewitz D,Campieri M,Meier R,Keller R,Rathbone B,Oddsson E

    更新日期:2001-08-01 00:00:00

  • Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD) is characterized by a chronic inflammation of the gut, partly driven by defects in the expression and function of pattern recognition receptors, including the IFI16 protein. Because this protein is a target for autoantibodies and its aberrant expression was reported in coloni...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000926

    authors: Caneparo V,Pastorelli L,Pisani LF,Bruni B,Prodam F,Boldorini R,Roggenbuck D,Vecchi M,Landolfo S,Gariglio M,De Andrea M

    更新日期:2016-12-01 00:00:00

  • Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.

    abstract:Background:We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. Methods:Retrospective review (May 2014-December 2016) of a prospectively maintained inflammatory bowel disease (IBD) registry. Kaplan-Meier estimates we...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy171

    authors: Shmidt E,Kochhar G,Hartke J,Chilukuri P,Meserve J,Chaudrey K,Koliani-Pace JL,Hirten R,Faleck D,Barocas M,Luo M,Lasch K,Boland BS,Singh S,Vande Casteele N,Sagi SV,Fischer M,Chang S,Bohm M,Lukin D,Sultan K,Swamina

    更新日期:2018-10-12 00:00:00

  • Hospital Admissions, Biological Therapy, and Surgery in Familial and Sporadic Cases of Inflammatory Bowel Disease: A Population-Based Cohort Study 1977-2011.

    abstract:BACKGROUND:Easily accessible predictors of disease course in inflammatory bowel disease (IBD) are scarce, and it remains largely unknown whether a family history of IBD predicts the course of Crohn's disease (CD) and ulcerative colitis (UC). We aimed to compare the course of disease in familial and sporadic cases of IB...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000545

    authors: Trier Moller F,Andersen V,Andersson M,Jess T

    更新日期:2015-12-01 00:00:00

  • Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment.

    abstract:BACKGROUND:Fistulas are a common complication of Crohn's disease (CD) and are difficult to treat effectively. This study aimed to assess the effects of fistula on annual costs of healthcare and resource utilization for patients with CD. METHODS:A retrospective analysis, using the PharMetrics database, of patients with...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20530

    authors: Cohen RD,Waters HC,Tang B,Rahman MI

    更新日期:2008-12-01 00:00:00

  • Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis.

    abstract:OBJECTIVES:Studies aimed at establishing which characteristics of patients with ulcerative proctitis could be predictive of the extension of inflammation have failed to provide conclusive results. The aim of the study was to evaluate the prognostic role of clinical and therapeutic parameters in patients with proctitis....

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200411000-00006

    authors: Pica R,Paoluzi OA,Iacopini F,Marcheggiano A,Crispino P,Rivera M,Bella A,Consolazio A,Paoluzi P

    更新日期:2004-11-01 00:00:00

  • Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis.

    abstract:BACKGROUND:Previous systematic cumulative analyses of the placebo arm in ulcerative colitis (UC) were limited by the wide heterogeneity in the scores and definitions of response. We aimed at estimating the placebo rates of remission, response, and mucosal healing (MH) in phase 2 and 3 randomized placebo-controlled tria...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,meta分析

    doi:10.1093/ibd/izy365

    authors: Macaluso FS,Maida M,Ventimiglia M,Renna S,Cottone M,Orlando A

    更新日期:2019-05-04 00:00:00

  • Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease.

    abstract:BACKGROUND:Noninvasive, sensitive, and specific tools for early identification of chronic inflammatory bowel disease (IBD) are needed for clinical practice. The aim was to identify new noninvasive test combinations for characterization of IBD in children and adolescents by comparing serological responses to microbial a...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20535

    authors: Ashorn S,Honkanen T,Kolho KL,Ashorn M,Välineva T,Wei B,Braun J,Rantala I,Luukkaala T,Iltanen S

    更新日期:2009-02-01 00:00:00

  • Differential susceptibility of P-glycoprotein deficient mice to colitis induction by environmental insults.

    abstract:BACKGROUND:P-glycoprotein (P-gp), the product of the multidrug resistance gene (MDR), is an ATP-dependent transmembrane pump, which is expressed in multiple cell lineages including epithelial and hematopoetic cells. The human MDR gene is located on chromosome 7 (7q21.1), a susceptibility loci for inflammatory bowel dis...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20824

    authors: Staley EM,Schoeb TR,Lorenz RG

    更新日期:2009-05-01 00:00:00

  • Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use.

    abstract:BACKGROUND:Various physician- and patient-reported instruments exist for quantification of disease activity in inflammatory bowel diseases (IBD) but none are widely used in routine clinical practice. A simple patient-reported outcome measure might help inform clinical decision making. We evaluated a patient-reported 0 ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000803

    authors: Subramanian S,Asher R,Weston W,Rimmer M,McConville A,Malin A,Jackson R,Collins P,Probert C,Dibb M,Rhodes JM

    更新日期:2016-08-01 00:00:00

  • A Cell-Based Approach to the Treatment of Inflammatory Bowel Disease-Entering an Era of Regenerative Medicine.

    abstract::Corticosteroids, and more recently biologics, have been the mainstay of therapy for patients with inflammatory bowel disease. Unfortunately, both are fraught with side effects and limited by lack of efficacy or loss of response. Many patients ultimately succumb to medically refractory disease and require an operation....

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1093/ibd/izy084

    authors: Lightner AL

    更新日期:2018-07-12 00:00:00

  • Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial.

    abstract:BACKGROUND:Interestingly, Clostridium difficile infection (CDI) worsens the course of inflammatory bowel disease (IBD); however, there is a paucity of data regarding the treatment of CDI in this group of patients. METHODS:This was a prospective, single-blind trial. Children with flare of IBD and CDI were randomly assi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/MIB.0000000000001249

    authors: Gawronska A,Banasiuk M,Lachowicz D,Pituch H,Albrecht P,Banaszkiewicz A

    更新日期:2017-12-01 00:00:00

  • Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.

    abstract:BACKGROUND:PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira), as used in routine clinical practice. METHODS:Adult patients with moderately to severely active Crohn's disease with or without prior adalimumab experience...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1093/ibd/izz008

    authors: Loftus EV,Reinisch W,Panaccione R,Berg S,Alperovich G,Bereswill M,Kalabic J,Petersson J,Thakkar R,Robinson AM,D'Haens G

    更新日期:2019-08-20 00:00:00

  • Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.

    abstract:BACKGROUND:Psoriasis induced by anti-tumor necrosis factor-α (TNF) therapy has been described as a paradoxical side effect. AIM:To determine the incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in a large nationwide cohort of inflammatory bowel disease patients. METHODS:Pat...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1097/MIB.0000000000000757

    authors: Guerra I,Pérez-Jeldres T,Iborra M,Algaba A,Monfort D,Calvet X,Chaparro M,Mañosa M,Hinojosa E,Minguez M,Ortiz de Zarate J,Márquez L,Prieto V,García-Sánchez V,Guardiola J,Rodriguez GE,Martín-Arranz MD,García-Tercero I,S

    更新日期:2016-04-01 00:00:00

  • Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multicenter North American Experience.

    abstract:BACKGROUND:Infliximab (IFX) infusion may lead to development of anti-IFX antibodies, and subsequent infusion reactions (IRs). The safety of rapid IFX infusion administered over 60 minutes has been under-investigated in children with inflammatory bowel disease. In a multicenter study, the frequency and nature of rapid i...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1097/MIB.0000000000001259

    authors: El-Matary W,Dykes DMH,Bauman L,Elkadri A,Carroll MW,Izaguirre MR,deBruyn J,Samson CM,Crim AM,Ali S,Grossman A

    更新日期:2017-12-01 00:00:00

  • Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.

    abstract:BACKGROUND:A notable proportion of patients with inflammatory bowel disease (IBD) are switched from infliximab (IFX) to adalimumab (ADL). We investigated if immunogenicity of IFX influenced immunogenicity and clinical outcomes of later ADL therapy. METHODS:Single-center cohort study including all patients with IBD ass...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1097/MIB.0000000000000138

    authors: Frederiksen MT,Ainsworth MA,Brynskov J,Thomsen OO,Bendtzen K,Steenholdt C

    更新日期:2014-10-01 00:00:00

  • Comparative study of candidate housekeeping genes for quantification of target gene messenger RNA expression by real-time PCR in patients with inflammatory bowel disease.

    abstract:BACKGROUND:Mucosal expression of immunological mediators is modified in inflammatory bowel disease (IBD). Quantification of target gene messenger RNA (mRNA) transcripts depends on the normalization to a housekeeping or reference gene. Stability of housekeeping gene expression is critical for the accurate measurement of...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.MIB.0000435440.22484.e8

    authors: Bamias G,Goukos D,Laoudi E,Balla IG,Siakavellas SI,Daikos GL,Ladas SD

    更新日期:2013-12-01 00:00:00

  • The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease.

    abstract:BACKGROUND:Patients with inflammatory bowel disease (IBD) are more susceptible to mental health problems than the general population; however, temporal trends in psychiatric diagnoses' incidence or prevalence in the United States are lacking. We sought to identify these trends among patients with IBD using national Vet...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz280

    authors: Thakur ER,Sansgiry S,Kramer JR,Waljee AK,Gaidos JK,Feagins LA,Govani SM,Dindo L,El-Serag HB,Hou JK

    更新日期:2020-08-20 00:00:00

  • Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis.

    abstract:BACKGROUND:The risk of corticosteroid-associated adverse events can limit the use of systemic corticosteroids. Oral, topically acting, second-generation corticosteroids that deliver drug to the site of inflammation, and biologic therapies, are effective treatment alternatives. The aim of this review was to evaluate the...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000001261

    authors: Cross RK

    更新日期:2017-10-01 00:00:00

  • Two-stage genome-wide methylation profiling in childhood-onset Crohn's Disease implicates epigenetic alterations at the VMP1/MIR21 and HLA loci.

    abstract:BACKGROUND:As a result of technological and analytical advances, genome-wide characterization of key epigenetic alterations is now feasible in complex diseases. We hypothesized that this may provide important insights into gene-environmental interactions in Crohn's disease (CD) and is especially pertinent to early onse...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000179

    authors: Adams AT,Kennedy NA,Hansen R,Ventham NT,OʼLeary KR,Drummond HE,Noble CL,El-Omar E,Russell RK,Wilson DC,Nimmo ER,Hold GL,Satsangi J

    更新日期:2014-10-01 00:00:00

  • Targeted inhibition of heat shock protein 90 suppresses tumor necrosis factor-α and ameliorates murine intestinal inflammation.

    abstract::Inflammatory bowel diseases are chronic intestinal inflammatory diseases thought to reflect a dysregulated immune response. Although antibody-based inhibition of tumor necrosis factor-α (TNF-α) has provided relief to many inflammatory bowel diseases patients, these therapies are either ineffective in a patient subset ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.MIB.0000442839.28664.75

    authors: Collins CB,Strassheim D,Aherne CM,Yeckes AR,Jedlicka P,de Zoeten EF

    更新日期:2014-04-01 00:00:00

  • Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.

    abstract:BACKGROUND AND AIMS:Crohn's disease (CD) is a chronic and invalidating inflammatory bowel disease of unknown etiology. The coordinated action of the cytochrome metabolizing subfamily CYP3A and the transport protein P-glycoprotein (P-gp) in the enterocyte results in a reduced bioavailability of drugs administered orally...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200608000-00011

    authors: Fakhoury M,Lecordier J,Medard Y,Peuchmaur M,Jacqz-Agrain E

    更新日期:2006-08-01 00:00:00

  • Regulation of sodium-glutamine cotransport in villus and crypt cells by glucocorticoids during chronic enteritis.

    abstract:BACKGROUND:Assimilation of the preferred nutrient of enterocytes is mediated primarily by sodium (Na)-dependent cotransport (NGct) in the intestine. The predominant NGcT in villus cells, B0AT1, is inhibited secondary to a decrease in cotransporter numbers during chronic intestinal inflammation. In contrast, NGcT mediat...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.22924

    authors: Arthur S,Saha P,Sundaram S,Kekuda R,Sundaram U

    更新日期:2012-11-01 00:00:00

  • Characterization of cecal gene expression in a differentially susceptible mouse model of bacterial-induced inflammatory bowel disease.

    abstract:BACKGROUND:A/JCr mice develop typhlitis in response to Helicobacter hepaticus infection, whereas C57BL/6 mice coexist with this bacterium in a "commensal" relationship and do not develop disease even during prolonged colonization. METHODS:To determine mechanisms that control this balance between responsiveness and non...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20138

    authors: Myles MH,Dieckgraefe BK,Criley JM,Franklin CL

    更新日期:2007-07-01 00:00:00